🇺🇸 FDA
Patent

US 11896672

Targeted nucleic acid conjugate compositions

granted A61KA61K31/713A61K47/549

Quick answer

US patent 11896672 (Targeted nucleic acid conjugate compositions) held by ARBUTUS BIOPHARMA CORPORATION expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ARBUTUS BIOPHARMA CORPORATION
Grant date
Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K31/713, A61K47/549, A61K47/554, A61K47/59